Americhem Unveils 2024 Sustainability Report Highlighting Major Accomplishments
Report Showcases Company’s Commitment to Environmental Responsibility, Highlights Future Ambitions
Americhem, Inc., a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, proudly announces the release of its 2024 Sustainability Report. This comprehensive report, titled Embracing Our Tomorrow, highlights Americhem’s unwavering commitment to environmental and social responsibility, providing an in-depth look at the company’s efforts across the entire value chain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205637181/en/
Lauren Lutikoff, Americhem Global Sustainability Leader (Photo: Business Wire)
Following the recent award of the Silver EcoVadis Medal, which places Americhem among the top 15% of companies assessed by EcoVadis—a globally recognized platform that rates businesses’ sustainability in various categories including Environment, Labor and Human Rights, Ethics, and Sustainable Procurement. Americhem’s sustainability report showcases the company’s major accomplishments and outlines future ambitions, including:
Americhem 2030 Plan: Over the past few years, Americhem has established baseline performance metrics and set targets within the business for each key pillar, aligning with the UN Sustainable Development Goals and Americhem’s vision for sustainability. The plan outlines the company’s dedication to advancing operations, developing sustainable solutions, and empowering employees, all while contributing to the communities in which it operates.
Americhem Decarbonization Strategy: The report reveals a robust decarbonization strategy focused on renewable energy, waste handling, and resource conservation projects at Americhem’s facilities. Other actions include increasing collaborative efforts with suppliers and customers to reduce greenhouse gas emissions.
“Meeting the sustainability goals of our customers requires the same mindset—embracing change while meeting the high-quality standards that consumers demand. Embarking on our sustainability journey is more than just a commitment; it’s a pledge for the future. Our mission is to lead with integrity, innovate responsibly, and inspire progress,” said John Richard, CEO at Americhem.
Major Accomplishments Built on Three Critical Pillars
Americhem’s sustainable framework is built on three critical pillars: People, Process, and Product. In 2024, Americhem rolled out programs and launched new products that contributed to these pillars, including:
People: Americhem’s commitment to world-class safety is demonstrated through its “Next Level Safety” campaign. The company has significantly surpassed industry benchmarks, with a Total Recordable Incident Rate (TRIR) 22% below the industry average.
Process: Americhem announced it is now sourcing 100% electricity through a local renewable energy program for its World Headquarters location. This transition is estimated to avoid approximately 750 metric tons of CO2 emissions annually1, equivalent to the carbon sequestered by 875 acres of U.S. forests in one year2.
Product: Americhem continues to lead in innovation with new product offerings such as the EcoLube™ line of PFAS-free internally lubricated compounds, addressing industry challenges around proposed PFAS regulations and promoting environmental responsibility.
Lauren Lutikoff, Americhem’s Global Sustainability Leader, said, “Americhem’s initiatives are aligned with the company’s commitment to innovation, while continually advancing environmental responsibility and product safety.”
“In today’s world, operating sustainably is no longer a choice, but a necessity. At Americhem, we recognize that sustainability is fundamental to our future and the well-being of our planet. This report is not just an accounting of our accomplishments, but rather a path for continued improvement and a testament of our dedication to a better tomorrow,” added Lutikoff.
To read Americhem’s sustainability report, visit www.americhem.com/pages/sustainability.
About Americhem
Americhem is an innovative, technology-driven leader in the global polymer industry. Its foundation is built around delivering Performance, Solutions and Trust through close collaboration with customers. All of the company's products are backed by complete technical support that ensures quality, reliability, and value. Americhem operates 10 manufacturing plants and maintains sales offices throughout the world.
1Calculation based on City of Cuyahoga Falls’ Utility Department Emissions Factor Rating for 2022 and Americhem Global Headquarters’ annual electricity consumption data.
2Calculation based on the EPA’s Greenhouse Gas Equivalency Calculator (https://www.epa.gov/energy/greenhouse-gas-equivalencies-calculator#results)
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205637181/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FIM Partners and Loomis Sayles Announce Transition of Global Emerging Market Equities Team6.11.2025 14:00:00 CET | Press release
FIM Partners today announced it has entered into an agreement with Loomis, Sayles & Company, to acquire the Global Emerging Market Equities (GEM) investment team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106799715/en/ Overview of the GEM Team and FIM Led by Ashish Chugh, Portfolio Manager and Head of Global Emerging Market Equities, the GEM Team follows a high conviction investment philosophy anchored in deep, fundamental research and a private equity-style approach to diligence and ownership. The team invests in high quality companies and those transitioning toward higher quality, leveraging its proprietary insights to identify long-term value creation opportunities across emerging markets. With an active, bottom-up, benchmark-agnostic strategy, the team builds high-conviction, concentrated, quality-focused portfolios that reflect a true ownership mindset. Founded in 2008, FIM Partners is a leading asset manager fo
IFCO’s circular model delivers global impact: Five years of progress marked with 2025 ESG report6.11.2025 14:00:00 CET | Press release
Over 10 billion single-use boxes replaced with reusable packaging in global fresh grocery supply chains IFCO, a global leader in reusable packaging containers (RPCs) for fresh food, today published its ESG Report 2025, marking the successful completion of its five-year sustainability strategy, Thriving in the Circular Economy. Over the last five years, IFCO has advanced every one of its 18 ESG goals, delivering measurable progress for the planet, people, partners, and customers while laying the groundwork for the next iteration of its sustainability objectives. The ESG Report 2025 confirms IFCO’s position as a global leader in circular packaging and highlights the role of reuse in addressing some of the sector’s most pressing challenges. Since IFCO’s founding in 1992, it has dedicated itself to eliminating packaging and food waste in the fresh grocery supply chain, enhancing efficiencies across the value chain and sharing the resulting long-term value with stakeholders. With operations
Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation6.11.2025 14:00:00 CET | Press release
LIBELULATM trial completed enrollment of Central Precocious Puberty (CPP) patients in North and South America, advancing the path for Debio 4326, a triptorelin injectable 12-month extended-release formulation Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the successful completion of patient enrollment in its open-label, single-arm, multi-center Phase III study (NCT06129539) ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULATM)’. The completion of enrollment is a significant milestone for the development of Debio 4326, a unique injectable, biodegradable 12-month extended-release formulation of the established treatment, triptorelin. The LIBELULATM trial is being conducted across the United States, Argenti
U.K. Continues to Lead Europe in Shareholder Activism with 44% Year-on-Year Surge, According to Diligent Market Intelligence6.11.2025 13:00:00 CET | Press release
As the U.K. Market Fuels Growing Interest from Domestic and International Activists, Investors Have Adapted their Approach to Gain Access to Boardrooms in Germany and Italy The U.K. remains Europe’s most active market for shareholder activism, with a 44% year-on-year increase in targeted companies, according to the Corporate Governance in Europe 2025report by Diligent Market Intelligence (DMI). Between September 2024 and August 2025, 52 U.K. companies faced activism, compared to 36 over the same timeframe in 2024, underscoring the market’s heightened shareholder engagement. “The U.K. remains the primary driver of public-facing engagement in Europe, with other European markets increasingly witnessing similar strategies when behind-the-scenes efforts fail,” said Josh Black, Editor-in-Chief, Diligent Market Intelligence. “Activism in Europe runs the full gamut from hostile media campaigns to more private engagements but there is no doubt that boards should prepare for anything in what loo
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates6.11.2025 12:00:00 CET | Press release
Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.6547 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition. Our late-stage hematology portfolio continues
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom